These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18061679)

  • 1. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.
    Kolesar JM; Schelman WR; Geiger PG; Holen KD; Traynor AM; Alberti DB; Thomas JP; Chitambar CR; Wilding G; Antholine WE
    J Inorg Biochem; 2008 Apr; 102(4):693-8. PubMed ID: 18061679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.
    Kolesar JM; Sachidanandam K; Schelman WR; Eickhoff J; Holen KD; Traynor AM; Alberti DB; Thomas JP; Chitambar CR; Wilding G; Antholine WE
    Exp Ther Med; 2011 Jan; 2(1):119-123. PubMed ID: 21373381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration of Fe(3+)-Triapine in BEAS-2B Cells.
    Antholine WE; Myers CR
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
    Shao J; Zhou B; Di Bilio AJ; Zhu L; Wang T; Qi C; Shih J; Yen Y
    Mol Cancer Ther; 2006 Mar; 5(3):586-92. PubMed ID: 16546972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
    Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
    Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
    Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.
    Aye Y; Long MJC; Stubbe J
    J Biol Chem; 2012 Oct; 287(42):35768-35778. PubMed ID: 22915594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation.
    Enyedy ÉA; May NV; Pape VFS; Heffeter P; Szakács G; Keppler BK; Kowol CR
    Dalton Trans; 2020 Dec; 49(46):16887-16902. PubMed ID: 33185224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells.
    Alvero AB; Chen W; Sartorelli AC; Schwartz P; Rutherford T; Mor G
    J Soc Gynecol Investig; 2006 Feb; 13(2):145-52. PubMed ID: 16443509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
    Ishiguro K; Lin ZP; Penketh PG; Shyam K; Zhu R; Baumann RP; Zhu YL; Sartorelli AC; Rutherford TJ; Ratner ES
    Biochem Pharmacol; 2014 Oct; 91(3):312-22. PubMed ID: 25130544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.
    Jiang ZG; Lebowitz MS; Ghanbari HA
    CNS Drug Rev; 2006; 12(1):77-90. PubMed ID: 16834759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
    Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
    Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triapine Derivatives Act as Copper Delivery Vehicles to Induce Deadly Metal Overload in Cancer Cells.
    Ohui K; Stepanenko I; Besleaga I; Babak MV; Stafi R; Darvasiova D; Giester G; Pósa V; Enyedy EA; Vegh D; Rapta P; Ang WH; Popović-Bijelić A; Arion VB
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32961653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
    Yuan J; Lovejoy DB; Richardson DR
    Blood; 2004 Sep; 104(5):1450-8. PubMed ID: 15150082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in protein binding and excretion of Triapine and its Fe(III) complex.
    Pelivan K; Miklos W; van Schoonhoven S; Koellensperger G; Gille L; Berger W; Heffeter P; Kowol CR; Keppler BK
    J Inorg Biochem; 2016 Jul; 160():61-9. PubMed ID: 26507768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
    Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
    Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
    Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
    J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
    Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
    J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.